Scholarlink

Purpose <p>Glioblastoma is the most common primary brain malignancy and carries significant mortality. Preclinical studies have highlighted the efficacy of antidepressant therapy in inhibiting glioblastoma progression; however, real-world evidence remains conflicting. We sought to investigate the impact of different commonly utilized antidepressant therapies on survival in patients with glioblastoma.</p> Methods <p>In total, 1464 consecutive patients with glioblastoma treated at a single institution from 2008 to 2023 were included for analysis. Multivariate cox regression analysis with antidepressant usage modeled as a time varying covariate was used to assess the effect of antidepressants while controlling for a priori selected clinical variables with known relevance to survival.</p> Results <p>The median age at diagnosis was 62 (IQR 52–70) years with a median overall survival of 13.8 months. Of the cohort, 44% utilized antidepressants after diagnosis, with SSRIs as the most common class utilized (26%). The median duration of any antidepressant therapy was 111 (IQR 9-303) days. In a time varying, multivariate cox regression, usage of SSRIs (HR 1.4, 95%CI 1.21–1.62), SNRIs (HR 1.33, 95%CI 1.03–1.72), serotonin modulators (HR 1.61, 95%CI 1.40–1.86), and atypical antidepressants (HR 1.7, 95%CI 1.28–2.26) were associated with worse survival. Amongst SSRIs, only escitalopram (HR 1.33, 95%CI 1.10–1.60) and citalopram (HR 1.31, 95%CI 1.01–1.70) were associated with worse survival.</p> Conclusions <p>Antidepressant therapy is associated with worse survival in patients with glioblastoma after adjusting for known factors with relevance to survival. Clinicians should consider the risks and benefits of prescribing antidepressants in patients with glioblastoma. Further evidence is necessary to better understand the impact of antidepressant therapy in glioblastoma survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival outcomes associated with antidepressant use in glioblastoma: a cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Yifei Sun,
  • Mohammad Hamo,
  • Travis Atchley,
  • James M. Markert,
  • Burt Nabors,
  • Dagoberto Estevez-Ordonez

摘要

Purpose

Glioblastoma is the most common primary brain malignancy and carries significant mortality. Preclinical studies have highlighted the efficacy of antidepressant therapy in inhibiting glioblastoma progression; however, real-world evidence remains conflicting. We sought to investigate the impact of different commonly utilized antidepressant therapies on survival in patients with glioblastoma.

Methods

In total, 1464 consecutive patients with glioblastoma treated at a single institution from 2008 to 2023 were included for analysis. Multivariate cox regression analysis with antidepressant usage modeled as a time varying covariate was used to assess the effect of antidepressants while controlling for a priori selected clinical variables with known relevance to survival.

Results

The median age at diagnosis was 62 (IQR 52–70) years with a median overall survival of 13.8 months. Of the cohort, 44% utilized antidepressants after diagnosis, with SSRIs as the most common class utilized (26%). The median duration of any antidepressant therapy was 111 (IQR 9-303) days. In a time varying, multivariate cox regression, usage of SSRIs (HR 1.4, 95%CI 1.21–1.62), SNRIs (HR 1.33, 95%CI 1.03–1.72), serotonin modulators (HR 1.61, 95%CI 1.40–1.86), and atypical antidepressants (HR 1.7, 95%CI 1.28–2.26) were associated with worse survival. Amongst SSRIs, only escitalopram (HR 1.33, 95%CI 1.10–1.60) and citalopram (HR 1.31, 95%CI 1.01–1.70) were associated with worse survival.

Conclusions

Antidepressant therapy is associated with worse survival in patients with glioblastoma after adjusting for known factors with relevance to survival. Clinicians should consider the risks and benefits of prescribing antidepressants in patients with glioblastoma. Further evidence is necessary to better understand the impact of antidepressant therapy in glioblastoma survival.